Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Helsinn Healthcare S.A.’s blockbuster chemotherapy treatment Aloxi is safe from competition from a Dr. Reddy’s Laboratories Inc. generic until 2024 ( Helsinn Healthcare S.A. v. Dr. Reddy's Labs., Ltd. , 2017 BL 46643, D.N.J., 12-2867 (MLC) (DEA), 2/14/17 ).
Dr. Reddy’s Laboratories’ proposed version of the drug infringes Helsinn’s patents, Judge Mary L. Cooper of the U.S. District Court for the District of New Jersey ruled in an opinion unsealed Feb. 15.
Cooper’s ruling blocks the FDA from approving Dr. Reddy’s version until the patents and their associated pediatric exclusivity periods expire in July 2024.
Protecting exclusivity on Aloxi is critical for Helsinn because the drug brings in about 90 percent of the company’s revenue. Aloxi (palonosetron) has roughly $500 million in annual U.S. sales. Helsinn shares the proceeds with its marketing partner Eisai through a confidential arrangement.
Dr. Reddy’s filed a new drug application (NDA) for its generic version of Aloxi through an abbreviated approval pathway under the Federal Food, Drug, and Cosmetic Act’s 505(b)(2) process. The 505(b)(2) process is an abbreviated pathway that allows the Food and Drug Administration to rely on data not developed by the applicant for approval of an NDA.
Cooper upheld the three Helsinn patents in the case, rejecting Dr. Reddy’s arguments that the patents were invalid.
“Helsinn is gratified that Judge Cooper has once again agreed with us on both the infringement and validity issues in this second trial involving our client’s very important Aloxi drug franchise,” Joseph O’Malley, an attorney with Paul Hastings LLP in New York who represented Helsinn in the case, said in a Feb. 16 statement.
Helsinn won a similar victory against Teva Pharmaceutical Industries Ltd. in 2015 when Cooper rejected Teva Pharmaceutical’s challenges to Helsinn’s Aloxi patents. Teva appealed the court’s decision to the U.S. Court of Appeals for the Federal Circuit in March 2016. The appeals court heard oral arguments Oct. 4, 2016, but the court hasn’t ruled yet.
Bloomberg BNA contacted Dr. Reddy’s for comment, but the company didn’t respond.
Paul Hastings LLP in New York and Saul Ewing LLP in Newark, N.J. represented Helsinn. Helsinn is based in Switzerland.
Lerner David Littenberg Krumholz & Mentlik LLP in Westfield, N.J. and Budd Larner PC in Short Hills, N.J., represented Dr. Reddy’s. Dr. Reddy’s is based in India.
To contact the reporter on this story: Dana A. Elfin in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
The opinion is available at http://src.bna.com/mg0.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)